



Unaudited half-yearly report for the six months ended 31 May 2021

Company number: 05528235

For UK investors only

Octopus AIM VCT 2 plc (“the Company”) is a venture capital trust (“VCT”) which aims to provide shareholders with attractive tax-free dividends and long-term capital growth by investing in a diverse portfolio of predominantly AIM-traded companies.

The Company is managed by Octopus Investments Limited (“Octopus” or the “Manager”).

Contents

Financial Summary	1
Key Dates	1
Chairman’s Statement	2
Interim Management Report	3
Investment Policy	8
Investment Portfolio	9
Directors’ Responsibilities Statement	15
Income Statement	16
Balance Sheet	17
Statement of Changes in Equity	18
Cash Flow Statement	21
Notes to the Half-Yearly Report	22
About Octopus AIM VCT 2 plc	28
Directors and Advisers	33

Financial Summary

	Six months to 31 May 2021	Six months to 31 May 2020	Year to 30 November 2020
Net assets (£'000)	132,553	83,227	104,146
Profit/(loss) after tax (£'000)	24,701	(2,036)	17,762
Net asset value ("NAV") per share (p)	99.2	68.7	82.9
Total return (%)*	22.2	(2.2)	20.3
Dividends paid in the period (p)	2.1	2.1	4.2
Interim dividend (p)**	2.1	2.1	2.1
Special dividend (p)**	1.7	-	-

*Total Return is an alternative performance measure calculated as movement in NAV per share in the period plus dividends paid in the period, divided by the NAV per share at the beginning of the period.

**The interim and special dividend will be paid on 12 November 2021 to shareholders on the register on 15 October 2021.

Key Dates

Financial Calendar

The Company's financial calendar is as follows:

Interim dividend payment date	12 November 2021
Annual results to 30 November 2021 announced	February 2022
Half-yearly results to 31 May 2022	July 2022

Chairman's Statement

I am pleased to present the half-yearly results for the Octopus AIM VCT 2 plc. In the six months to 31 May 2021 the VCT has seen another period of rising share prices despite being faced with unpredictable situations around the easing of lockdown in December, when rapidly rising cases prompted a return of restrictions in January. What has been apparent in the latest period is that although the pandemic has continued to affect lives and our healthcare system, the impact of the November and then January lockdowns was less severe in general economic terms than the initial lockdown in March 2020. This has left scope for analysts to upgrade previously cautious forecasts for 2021 as the year has progressed. The portfolio has continued to show resilience, still benefiting from its high exposure to the technology and healthcare sectors and the NAV per share rose by 22.2% in the six months if the 2.1p dividend paid in May 2021 is added back.

The Board has declared an interim dividend of 2.1p and a special dividend of 1.7p which will be paid on 12 November 2021 to shareholders on the register on 15 October 2021.

The flow of VCT qualifying investment opportunities has continued and your Investment Manager has made twelve qualifying investments in the six month period which are explained further in their report. Reassuringly, AIM has fulfilled its function to raise capital for existing members throughout the pandemic and as companies look beyond the crisis we are also seeing the return of new issues as companies plan their next phase of growth.



Keith Mullins
Chairman
21 July 2021

Interim Management Report

Overview

The six months to 31 May 2021 has been another volatile period for stockmarkets. December was an exceptionally strong month for share price performances as the November lockdown eased, optimism about the approval of three vaccines registered and a trade agreement in the wake of Brexit was agreed at the eleventh hour. A return to lockdown between January and March was more sobering, but the UK market took comfort from a well managed vaccine rollout and evidence that businesses were coping better with lockdowns and consequently the economic damage was less severe than in the early summer of 2020. In addition, trading updates from companies were generally better than had been hoped for with existing cautious forecasts most often being upgraded by analysts rather than the other way around. There has also been a return of takeover bids as companies have sought to invest cash accumulated on their balance sheets.

After the usual January lull, the flow of capital raised by companies has built on the strength of 2020, supplemented by the return of new flotations. Stock market liquidity has been good and we have taken some profits from holdings that have done particularly well. The Company has deployed existing cash throughout the period as well as raising £9.4 million net of costs for future investments.

Performance

Adding back the 2.1p paid out in dividends in the period, the NAV rose by 22.2% in the six months to 31 May 2021. This compares with a 20.0% rise in the AIM Index, a 35.9% rise in the Smaller Companies Index (ex Investment Trusts) and a 15.2% rise in the FTSE All Share Index, all on a total return basis. This resilient performance can still be partially attributed to the VCT's relatively high exposure to the healthcare and technology sectors, particularly where companies have announced stronger than expected trading or strong technological progress. However, there was also a recovery in some of the stocks that had previously been badly affected in the pandemic and this was a strong period for some of the smaller consumer facing holdings such as Vertu Motors and Escape Hunt as well as Breedon group among the larger holdings. These are all expected to benefit from a surge in consumer demand as the economy opens up.

The strongest theme driving performance in the period was upgrades to forecasts which had generally been set at a low level reflecting pandemic caution in 2020, and this extended across different sectors and included a large proportion of portfolio companies. Those companies exceeding expectations included SDI Group which makes scientific and technology products for multiple specialist markets, PCI-Pal, Netcall, and Gamma in network communications, Next Fifteen in media communications and the Panoply in digital change consulting. Gear4music has continued to exceed expectations although forecasts for 2021 reflect caution as high street business are able to compete again, leaving plenty of scope for upgrades if current trends continue.

Among the healthcare stocks, Ergomed, EKF Diagnostics and Maxcyte have all enjoyed multiple upgrades to forecasts in the period. Cell based medicine specialist Maxcyte completed an oversubscribed £40 million fundraise and announced its intention to dual-list on Nasdaq. Renalytix, which had already gone down this pathway, also performed well as shareholders focused on the potential for its KidneyInteIX test once it achieves regulatory approval. We have taken some profits in Ergomed and Renalytix shares in the period.

The largest detractor from performance in the period was Ixico which unfortunately lost a multi-million pound contract when a Phase 3 trial in Huntington's disease was terminated early. The company has since announced further clinical trial wins but it will take some time for the shares to recover the lost ground.

Portfolio Activity

In the period under review, the Company made twelve qualifying investments totalling £5.3 million, ahead of the £3.9 million we invested in the corresponding period last year, reflecting the part that AIM has continued to play in providing finance to its constituents through the Coronavirus pandemic. Two of these were follow-on investments into existing holdings in The British Honey Company plc (BHC) and Cloudcall Group plc (Cloudcall) totalling £0.7 million. BHC raised money to install new machinery into its production line alongside the acquisition of another complementary distillery business. Cloudcall suffered during the pandemic with its principal customer group being the recruitment sector. They anticipate this will now make a swift recovery and the money raised will put them back on a growth track.

Of the ten new investments totalling £4.6 million Abingdon, In The Style, Parsley Box and Glantus were all new entrants to the AIM market and Oberon Group was admitted to the AQSE Growth market, having reversed into a fully listed cash shell. Abingdon has built a lateral flow testing centre in the North East of England after winning an initial Government contract for Covid antibody testing. It intends to use its facility to develop tests for those wanting supply from the UK and is in discussions with other potential customers abroad. In The Style Group is a fast growing on-line fashion retailer which uses social media 'influencers' to design and promote ranges of clothes. Parsley Box is an on-line retailer of ready meals particularly targeting older people. Glantus has developed a platform for automating the reconciliation of supplier invoices which is particularly aimed at large clients operating multiple ERP computer systems which struggle to communicate with each other. Oberon Group is a small and growing financial boutique providing services in investment management, wealth planning and corporate advisory and broking.

We made three new qualifying investments in existing AIM companies where we had been watching their progress for some time. Evgen Pharma has a funded trial for ARDS (acute respiratory distress syndrome) and some more compelling data for its sulphoraphane based compounds, Polarean is a specialist lung imaging company and Crimson Tide has software which audits that health and safety measures such as cleaning has been done for large organisations. We also made two new private company investments each of £0.2 million in The Food Marketplace, an on-line market place for specialist food distribution and Elucedá, a company with detection technology used to protect brands from counterfeit.

In the period we also invested £1.7 million of the cash balances into the FP Octopus UK Multi-Cap Income Fund and £0.7 million into Octopus UK Micro Cap Growth fund, with the objective of obtaining a better return on our cash awaiting investment.

A number of disposals were made in the half year, following some exceptional share price performances. The result has been a net gain of £2.8 million over book cost. We sold the entire holding of C4X Discovery after a strong performance in the shares and took profits in Ergomed, GB Group, Ilika, Trackwise Designs, Renalytix, Intelligent Ultrasound, Access Intelligence and PCI-Pal to manage the size of the holdings. We responded to a bid to sell our entire holding in Fusionex at a small profit. It took itself private several years ago and it has no immediate intention of returning to public markets and part disposed of our holding in Maestrano.

Unquoted Investments

As stated in the investment policy on page 8, the Company is able to make investments in unquoted companies intending to float. Currently 3.2% (31 May 2020: 3.1% and 30 November 2020: 4.7%) of the Company's net assets are invested in unquoted companies.

Transactions with Manager

Details of amounts paid to the Manager are disclosed in note 8 to the Financial Statements.

Share Buybacks

In the six months to May 2021, the Company bought back 3,194,979 Ordinary shares for a total consideration of £2,874,919. It is evident from the conversations which your Managers have that this facility remains an important consideration for investors. Your Board remains committed to maintaining its policy of buying back shares at a discount of up to 4.5% to NAV.

Share Issues

In this period 10,573,503 shares were issued in connection with the 2020/21 prospectus offer which closed fully subscribed.

In this period 538,519 new shares were issued through the dividend reinvestment scheme (DRIS).

Dividend

On 21 May 2021, the Company paid a dividend of 2.1p per share, being the final dividend for the year ended 30 November 2020. For the period to 31 May 2021, the Board has declared an interim dividend of 2.1p. This will be paid on 12 November 2021 to shareholders on the register on 15 October 2021. The Board is also pleased to declare a special dividend of 1.7p which will be paid at the same time as the interim dividend. This represents a proportion of the gains realised from profit taking in the period after some very strong share price performances in the portfolio.

It remains the Board's intention to maintain a minimum annual dividend payment of 3.6p per share or a 5% yield based on the prior year end share price, whichever is the greater. This will usually be paid in two instalments during each year.

Risks, Uncertainties

The principal risks and uncertainties are set out in Note 7 to the half-yearly report and accounts on page 23.

Outlook

Investors have anticipated the final easing of lockdown based on the success of the vaccination programme with many of the shares formerly most affected by restrictions now well off their lows as they have found new supporters in 2021. However, for the most part those that have been able to keep the momentum in their business going throughout the pandemic are still being rewarded for upgrades to cautiously set forecasts for 2021 and 2022 and their share prices have continued to react positively. Economic consensus is that a record contraction to the economy in 2020 will be matched by very strong growth in 2021 as a proportion of the corporate and household savings during the pandemic are spent. We have already seen a rise in takeover bids which supports higher valuations for equities. There are two notes of caution; the first about whether the very strong recovery will lead to more than the temporary rise in inflation which is currently expected towards the end of 2021 and the second is the extent to which comparatively modest technology valuations in the UK would suffer were those in the US to fall. The portfolio's strength is that it is well diversified both in terms of sector exposure and of individual company concentration. At the period end it

contained 89 holdings (31 May 2020: 78 holdings and 30 November 2020: 80 holdings) across a range of sectors including healthcare and technology with the balance still weighted towards profitable companies which are continuing to pursue growth.

There are a number of newer holdings that still need to demonstrate progress over the coming months in order to reach profitability. The VCT currently has funds available for new investments as well as supporting those who are still on this journey to profitability. The investment rate has accelerated in the past six months and as a result the VCT is 88.3% invested in qualifying companies allowing us to be selective when viewing new investment opportunities.

The AIM Team
Octopus Investments
21 July 2021

Investment Policy

The Company's investment policy has been designed to enable it to comply with the VCT qualifying conditions. The Board intends that the long-term disposition of the Company's assets will be not less than 85% in a portfolio of qualifying AIM, AQSE Exchange traded investments or unquoted companies where in the short to medium term, the management is planning an initial public offering ("IPO") on AIM or AQSE Exchange.

The non-qualifying balance will be invested in permitted investments held for short term liquidity, generally comprising short term cash or money market deposits with a minimum Moody's long term debt rating of 'A', authorised funds including those managed by Octopus or directly in equity investments and bonds. This provides a reserve of liquidity which should maximise the Company's flexibility as to the timing of investments, disposals, dividend payments and share buybacks.

Risk is spread by investing in a number of different businesses across a range of industry sectors using a mixture of securities. The maximum amount invested in any one company is limited to the amount permitted pursuant to VCT legislation in a fiscal year and no more than 15% of the Company's assets, at cost, will be invested in the same company. The value of an individual investment is expected to increase over time as a result of trading progress and a continuous assessment is made of its suitability for sale. However, shareholders should be aware that the Company's qualifying investments are held with a view to long-term capital growth as well as income and will often have limited marketability; as a result it is possible that individual holdings may grow in value to the point where they represent a significantly higher proportion of total assets prior to a realisation opportunity being available.

The Company's Articles permit borrowings of amounts up to 10% of the adjusted share capital and reserves (as defined in the Company's Articles). However, investments will normally be made using the Company's equity shareholders' funds and it is not intended that the Company will take on any borrowings.

No material changes may be made to the Company's investment policy described above without the prior approval of shareholders by the passing of an Ordinary Resolution. The Directors will continually monitor the investment process and ensure compliance with the investment policy.

Investment Portfolio

Quoted Investments

Investee Company	Sector	Book cost as at 31 May 2021 £'000	Cumulative change in Fair Value £'000	Fair Value as at 31 May 2021 £'000	Movement in period £'000	% equity held by Octopus AIM VCT 2 plc	% equity held by all funds managed by Octopus	Fair value as a % of Octopus AIM VCT 2's NAV
Ergomed plc	Pharmaceuticals, Biotechnology and Marijuana Producers	852	5,531	6,383	1,899	1.08%	3.48%	4.82%
Learning Technologies Group plc	Software and Computer Services	701	4,556	5,257	999	0.42%	5.18%	3.97%
Breedon Group plc	Construction and Materials	573	4,572	5,145	1,327	0.28%	4.83%	3.88%
GB Group plc	Software and Computer Services	337	4,768	5,105	481	0.28%	6.37%	3.85%
Craneware plc	Health Care Providers	479	3,115	3,594	0	0.58%	1.38%	2.71%
Trackwise Designs plc	Technology Hardware and Equipment	1,301	2,124	3,425	160	5.13%	13.89%	2.58%
EKF Diagnostics Holdings plc	Medical Equipment and Services	864	2,501	3,365	531	0.97%	3.69%	2.54%
Maxcyte Inc	Pharmaceuticals, Biotechnology and Marijuana Producers	340	2,557	2,897	1,548	0.44%	1.94%	2.19%
Scientific Digital Imaging plc	Technology Hardware and Equipment	119	2,693	2,812	1,518	1.51%	3.78%	2.12%
Animalcare Group plc	Pharmaceuticals, Biotechnology and Marijuana Producers	824	1,958	2,782	1,164	1.46%	3.44%	2.10%
The Panoply Holdings plc	Software and Computer Services	653	1,862	2,515	838	1.09%	3.33%	1.90%
Illicka plc	Energy	506	1,896	2,402	1,125	0.91%	2.78%	1.81%
Gear4music Holdings plc	Leisure Goods	372	1,954	2,326	454	1.28%	3.19%	1.75%
IDOX plc	Software and Computer Services	356	1,960	2,316	468	0.84%	1.90%	1.75%
PCI-Pal plc	Software and Computer Services	854	1,344	2,198	1,205	3.62%	9.05%	1.66%
Ixico plc	Pharmaceuticals, Biotechnology and Marijuana Producers	697	1,469	2,166	(747)	5.19%	12.97%	1.63%
Renalytix plc	Health Care Providers	228	1,847	2,075	1,227	0.25%	0.71%	1.57%
Judges Scientific plc	Electronic and Electrical Equipment	209	1,827	2,036	188	0.53%	1.33%	1.54%
Intelligent Ultrasound Group plc	Medical Equipment and Services	1,238	768	2,006	182	4.51%	11.29%	1.51%
Sosandar plc	Retailers	1,235	616	1,851	282	3.64%	12.88%	1.40%
Creo Medical Group plc	Medical Equipment and Services	981	636	1,617	345	0.50%	2.26%	1.22%

Investment Portfolio continued

Investee Company	Sector	Book cost as at 31 May 2021 £'000	Cumulative change in Fair Value £'000	Fair Value as at 31 May 2021 £'000	Movement in period £'000	% equity held by Octopus AIM VCT 2 plc	% equity held by all funds managed by Octopus	Fair value as a % of Octopus AIM VCT 2's NAV
Access Intelligence plc	Software and Computer Services	542	1,051	1,593	515	1.45%	3.49%	1.20%
Brooks Macdonald Group plc	Investment Banking and Brokerage Services	610	971	1,581	386	0.46%	14.31%	1.19%
Netcall plc	Software and Computer Services	356	1,092	1,448	376	1.45%	3.44%	1.09%
ReNeuron Group plc	Pharmaceuticals, Biotechnology and Marijuana Producers	1,016	407	1,423	589	2.09%	6.27%	1.07%
Next Fifteen Communications Group plc	Media	344	1,039	1,383	564	0.18%	14.33%	1.04%
Quixant plc	Technology Hardware and Equipment	391	959	1,350	161	1.28%	3.19%	1.02%
Glantus Holdings plc	Industrial Support Services	1,200	(59)	1,141	(59)	3.24%	8.11%	0.86%
RWS Holdings plc	Industrial Support Services	99	979	1,078	129	0.04%	3.70%	0.81%
AdEPT Technology Group plc	Telecommunications Service Providers	502	557	1,059	358	1.43%	3.14%	0.80%
VR Education Holdings plc	Software and Computer Services	653	392	1,045	163	2.70%	10.29%	0.79%
Diaceutics plc	Health Care Providers	620	424	1,044	(33)	0.97%	2.43%	0.79%
Verici Dx plc	Pharmaceuticals, Biotechnology and Marijuana Producers	264	739	1,003	370	0.93%	2.33%	0.76%
Gamma Communications plc	Telecommunications Service Providers	183	767	950	184	0.05%	6.06%	0.72%
Gooch & Housego plc	Technology Hardware and Equipment	281	602	883	90	0.28%	13.00%	0.67%
The British Honey Company plc	Retailers	840	31	871	12	4.64%	11.59%	0.66%
Advanced Medical Solutions Group plc	Medical Equipment and Services	495	362	857	92	0.14%	11.60%	0.65%
Vertu Motors plc	Retailers	777	29	806	232	0.51%	1.64%	0.61%
Evgen Pharma plc	Pharmaceuticals, Biotechnology and Marijuana Producers	700	70	770	70	3.18%	7.96%	0.58%
Fusion Antibodies plc	Health Care Providers	497	263	760	196	2.34%	5.84%	0.57%
In The Style Group plc	Retailers	667	67	734	67	0.63%	4.80%	0.55%
Beeks Financial Cloud Group plc	Software and Computer Services	302	404	706	151	1.08%	6.25%	0.53%

Investment Portfolio continued

Investee Company	Sector	Book cost as at 31 May 2021 £'000	Cumulative change in Fair Value £'000	Fair Value as at 31 May 2021 £'000	Movement in period £'000	% equity held by Octopus AIM VCT 2 plc	% equity held by all funds managed by Octopus	Fair value as a % of Octopus AIM VCT 2's NAV
Polarean Imaging plc	Medical Equipment and Services	458	237	695	237	0.36%	0.91%	0.52%
Cambridge Cognition Holdings plc	Health Care Providers	400	286	686	372	1.83%	4.59%	0.52%
Clinigen Group plc	Pharmaceuticals, Biotechnology and Marijuana Producers	469	191	660	154	0.06%	5.54%	0.50%
Vectura Group plc	Pharmaceuticals and Biotechnology	332	255	587	169	0.06%	0.20%	0.44%
Restore plc	Industrial Support Services	171	360	531	58	0.09%	10.55%	0.40%
Synaigen plc	Pharmaceuticals, Biotechnology and Marijuana Producers	98	359	457	220	0.14%	1.05%	0.34%
Cloudcall Group plc	Software and Computer Services	624	(169)	455	(127)	1.42%	3.54%	0.34%
Crimson Tide plc	Software and Computer Services	378	13	391	13	1.92%	4.79%	0.29%
Mattioli Woods plc	Investment Banking and Brokerage Services	101	230	331	(19)	0.17%	3.91%	0.25%
Rosslyn Data Technologies plc	Software and Computer Services	286	29	315	14	1.68%	4.21%	0.24%
Oberon Investments Group plc	Investment Banking and Brokerage Services	320	(24)	296	(24)	1.95%	6.10%	0.22%
MyCelx Technologies Corporation	Oil, Gas and Coal	980	(693)	287	136	2.79%	15.82%	0.22%
DP Poland plc	Travel and Leisure	677	(409)	268	40	0.54%	1.36%	0.20%
Maestrano Group plc	Software and Computer Services	296	(30)	266	69	1.17%	2.92%	0.20%
WANdisco plc	Software and Computer Services	96	130	226	(19)	0.09%	0.23%	0.17%
DXS International plc	Software and Computer Services	200	25	225	63	5.18%	12.95%	0.17%
Falanx Group Limited	Industrial Support Services	600	(380)	220	48	3.80%	9.51%	0.17%
Genedrive Plc	Pharmaceuticals, Biotechnology and Marijuana Producers	241	(27)	214	54	0.48%	1.19%	0.16%
KRM 22 plc	Closed End Investments	454	(250)	204	45	1.70%	4.25%	0.15%
Feedback plc	Medical Equipment and Services	200	0	200	(20)	1.87%	4.69%	0.15%

Investment Portfolio continued

Investee Company	Sector	Book cost as at 31 May 2021 £'000	Cumulative change in Fair Value £'000	Fair Value as at 31 May 2021 £'000	Movement in period £'000	% equity held by Octopus AIM VCT 2 plc	% equity held by all funds managed by Octopus	Fair value as a % of Octopus AIM VCT 2's NAV
Abingdon Health plc	Medical Equipment and Services	347	(148)	199	(148)	0.38%	0.94%	0.15%
Escape Hunt plc	Travel and Leisure	659	(464)	195	110	0.55%	1.38%	0.15%
TP Group plc	Aerospace and Defense	452	(257)	195	(26)	0.47%	2.36%	0.15%
Trellus Health plc	Health Care Providers	109	68	177	68	0.17%	0.50%	0.13%
Verici Dx plc	Pharmaceuticals and Biotechnology	40	114	154	57	0.93%	2.33%	0.12%
LoopUp Group plc	Software and Computer Services	197	(49)	148	(18)	0.36%	0.89%	0.11%
Velocity Composites plc	Aerospace and Defense	533	(395)	138	31	1.73%	4.32%	0.10%
Osirium Technologies plc	Software and Computer Services	900	(770)	130	6	2.11%	23.31%	0.10%
Parsley Box Group plc	Personal Care, Drug and Grocery Stores	142	(13)	129	(13)	0.17%	3.27%	0.10%
Enteq Upstream plc	Oil, Gas and Coal	686	(571)	115	21	1.01%	2.53%	0.09%
Tasty plc	Travel and Leisure	336	(269)	67	30	0.79%	1.85%	0.05%
Microsaic Systems plc	Electronic and Electrical Equipment	922	(883)	39	(29)	0.28%	0.71%	0.03%
Mears Group plc	Software and Computer Services	51	(17)	34	6	0.02%	0.13%	0.03%
Diurnal Group plc	Pharmaceuticals, Biotechnology and Marijuana Producers	88	(56)	32	9	0.03%	0.07%	0.02%
ISpatial plc	Software and Computer Services	200	(175)	25	9	0.06%	1.00%	0.02%
Haydale Graphene Industries plc	Industrial Materials	399	(382)	17	6	0.06%	0.15%	0.01%
Midatech Pharma plc	Pharmaceuticals, Biotechnology and Marijuana Producers	400	(398)	2	0	0.01%	0.03%	0.00%
Location Sciences Group plc	Software and Computer Services	509	(508)	1	0	0.01%	0.02%	0.00%
Total Quoted Investments		39,409	56,660	96,069	21,409			


Investment Portfolio continued

Investee Company	Sector	Book cost as at 31 May 2021 £'000	Cumulative change in Fair Value £'000	Fair Value as at 31 May 2021 £'000	Movement in period £'000	% equity held by Octopus AIM VCT 2 plc	% equity held by all funds managed by Octopus	Fair value as a % of Octopus AIM VCT 2's NAV
Unquoted Investments								
Hasgrove plc	Media	153	2,288	2,441	0	2.42%	14.10%	1.84%
Popsa Holdings Ltd	Software and Computer Services	780	618	1,398	0	4.85%	12.11%	1.05%
The Food Marketplace Ltd	Retailers	200	0	200	0	4.40%	11.00%	0.15%
Elucedo Limited	Pharmaceuticals, Biotechnology and Marijuana Producers	200	0	200	0	1.64%	4.10%	0.15%
Airnow plc	Software and Computer Services	838	(663)	175	9	0.27%	0.70%	0.13%
Rated People Ltd	Software and Computer Services	236	(215)	20	(3)	0.34%	1.49%	0.02%
Total Unquoted Investments		2,407	2,028	4,434	6			
Loan Notes								
Osirium Technologies plc Loan Notes	Software and Computer Services	400	0	400	0			0.30%
Total Loan Notes		400	0	400	0			
Current Asset Investments								
Octopus UK Micro Cap Growth Fund		3,740	3,381	7,121	0			5.37%
Octopus UK Multi Cap Income Fund		3,926	1,083	5,009	0			3.78%
Total Current Asset Investments		7,666	4,464	12,130	0			
Total Fixed and Current Asset Investments				113,033				
Money Market Funds				3,486				
Cash at Bank				16,583				
Debtors less Creditors				(549)				
Total Net Assets				132,553				


Investment Portfolio continued

Sector Analysis

The graph below shows the sectors the equity portfolio was invested in by value as at 31 May 2021. It also shows the sectors of the AIM Market as a whole as at 31 May 2021:



The graph below shows the sectors the equity portfolio was invested in by value as at 31 May 2020. It also shows the sectors of the AIM Market as a whole as at 31 May 2020:



Director's Responsibilities Statement

We confirm that to the best of our knowledge:

- the half-yearly financial statements have been prepared in accordance with Financial Reporting Standard 104 'Interim Financial Reporting' issued by the Financial Reporting Council;
- the half-yearly financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the Company;
- the half-yearly report includes a fair review of the information required by the Financial Conduct Authority Disclosure and Transparency Rules, being:
 - an indication of the important events that have occurred during the first six months of the financial year and their impact on the condensed set of financial statements;
 - a description of the principal risks and uncertainties for the remaining six months of the year; and
 - a description of related party transactions that have taken place in the first six months of the current financial year, that may have materially affected the financial position or performance of the Company during that period and any changes in the related party transactions described in the last annual report that could do so.

On behalf of the Board



Keith Mullins
Chairman
21 July 2021

Income Statement

	Unaudited Six months to 31 May 2021			Unaudited Six months to 31 May 2020			Audited Year to 30 November 2020		
	Revenue £'000	Capital £'000	Total £'000	Revenue £'000	Capital £'000	Total £'000	Revenue £'000	Capital £'000	Total £'000
Gain/(loss) on disposal of fixed asset investments	-	1,552	1,552	-	(378)	(378)	-	433	433
Gain/(loss) on disposal of current asset investments	-	33	33	-	(42)	(42)	-	(158)	(158)
Gain/(loss) on valuation of fixed asset investments	-	21,415	21,415	-	(601)	(601)	-	17,871	17,871
Gain/(loss) on valuation of current asset investments	-	2,680	2,680	-	(225)	(225)	-	1,126	1,126
Investment income	126	109	235	108	-	108	290	41	331
Investment management fees	(218)	(655)	(873)	(162)	(485)	(647)	(334)	(1,001)	(1,335)
Other expenses	(341)	-	(341)	(251)	-	(251)	(506)	-	(506)
Profit/(loss) before tax	(433)	25,134	24,701	(305)	(1,731)	(2,036)	(550)	18,312	17,762
Tax	-	-	-	-	-	-	-	-	-
Profit/(loss) after tax	(433)	25,134	24,701	(305)	(1,731)	(2,036)	(550)	18,312	17,762
Earnings per share – basic and diluted	(0.3)p	18.7p	18.4p	(0.3)p	(1.5)p	(1.8)p	(0.5)p	15.5p	15.0p

There is no other comprehensive income for the period.

- The 'Total' column of this statement is the profit and loss account of the Company; the supplementary revenue return and capital return columns have been prepared in accordance with the AIC Statement of Recommended Practice.
- All revenue and capital items in the above statement derive from continuing operations.
- The Company has only one class of business and derives its income from investments made in shares and securities and from bank and money market funds, as well as Open Ended Investment Company ("OEIC") funds.

Balance Sheet

	Unaudited As at 31 May 2021		Unaudited As at 31 May 2020		Audited As at 30 November 2020	
	£'000	£'000	£'000	£'000	£'000	£'000
Fixed asset investments		100,903		58,867		76,695
Current assets:						
Investments	12,130		15,580		10,396	
Money market funds	3,486		3,485		3,486	
Debtors	58		1,055		120	
Cash at bank	16,583		4,806		14,838	
	32,257		24,926		28,840	
Creditors: amounts falling due within one year	(607)		(566)		(1,389)	
Net current assets		31,650		24,360		27,451
Total assets less current liabilities		132,553		83,227		104,146
Called up equity share capital		13		12		13
Share premium		47,142		56,320		37,758
Special distributable reserve		29,372		15,369		35,051
Capital reserve realised		(4,851)		(9,168)		(7,492)
Capital reserve unrealised		62,802		21,942		40,309
Capital redemption reserve		2		1		1
Revenue reserve		(1,927)		(1,249)		(1,494)
Total equity shareholders' funds		132,553		83,227		104,146
NAV per share – basic and diluted		99.2p		68.7p		82.9p

The statements were approved by the Directors and authorised for issue on 21 July 2021 and are signed on their behalf by:



Keith Mullins
Chairman

Company Number: 05528235

Statement of Changes in Equity

	Share Capital £'000	Share Premium £'000	Special distributable reserves* £'000	Capital reserve realised* £'000	Capital reserve unrealised £'000	Capital redemption reserve £'000	Revenue reserve* £'000	Total £'000
As at 1 December 2020	13	37,758	35,051	(7,492)	40,309	1	(1,494)	104,146
Total comprehensive income for the period	-	-	-	1,039	24,095	-	(433)	24,701
Contributions by and distributions to owners:								
Repurchase and cancellation of own shares	(1)	-	(2,875)	-	-	1	-	(2,875)
Issue of shares	1	10,027	-	-	-	-	-	10,028
Share issue costs	-	(643)	-	-	-	-	-	(643)
Dividends paid	-	-	(2,804)	-	-	-	-	(2,804)
Total contributions by and distributions to owners	-	9,384	(5,679)	-	-	1	-	3,706
Other movements:								
Prior years' holding gains now realised	-	-	-	1,602	(1,602)	-	-	-
Total other movements	-	-	-	1,602	(1,602)	-	-	-
Balance as at 31 May 2021	13	47,142	29,372	(4,851)	62,802	2	(1,927)	132,553

*The sum of these reserves is an amount of £22,594,000 (31 May 2020: £4,952,000 and 30 November 2020: £26,065,000) which is considered distributable to shareholders.

	Share Capital £'000	Share Premium £'000	Special distributable reserves* £'000	Capital reserve realised* £'000	Capital reserve unrealised £'000	Capital redemption reserve £'000	Revenue reserve* £'000	Total £'000
As at 1 December 2019	11	47,044	19,423	(8,641)	23,146	1	(944)	80,040
Total comprehensive income for the period	-	-	-	(905)	(826)	-	(305)	(2,036)
Contributions by and distributions to owners:								
Repurchase and cancellation of own shares	-	-	(1,521)	-	-	-	-	(1,521)
Issue of shares	1	9,893	-	-	-	-	-	9,894
Share issue costs	-	(617)	-	-	-	-	-	(617)
Dividends paid	-	-	(2,533)	-	-	-	-	(2,533)
Total contributions by and distributions to owners	1	9,276	(4,054)	-	-	-	-	5,223
Other movements:								
Prior years' holding gains now realised	-	-	-	378	(378)	-	-	-
Total other movements	-	-	-	378	(378)	-	-	-
Balance as at 31 May 2020	12	56,320	15,369	(9,168)	21,942	1	(1,249)	83,227

	Share Capital £'000	Share Premium £'000	Special distributable reserves* £'000	Capital reserve realised* £'000	Capital reserve unrealised £'000	Capital redemption reserve £'000	Revenue reserve* £'000	Total £'000
As at 1 December 2019	11	47,044	19,423	(8,641)	23,146	1	(944)	80,040
Total comprehensive income for the period	-	-	-	(685)	18,997	-	(550)	17,762
Contributions by and distributions to owners:								
Repurchase and cancellation of own shares	-	-	(2,710)	-	-	-	-	(2,710)
Issue of shares	2	15,027	-	-	-	-	-	15,029
Share issue costs	-	(908)	-	-	-	-	-	(908)
Dividends paid	-	-	(5,067)	-	-	-	-	(5,067)
Total contributions by and distributions to owners	2	14,119	(7,777)	-	-	-	-	6,344
Other movements:								
Cancellation of share premium	-	(23,405)	23,405	-	-	-	-	-
Prior years' holding gains now realised	-	-	-	1,834	(1,834)	-	-	-
Total other movements	-	(23,405)	23,405	1,834	(1,834)	-	-	-
Balance as at 30 November 2020	13	37,758	35,051	(7,492)	40,309	1	(1,494)	104,146

Cash Flow Statement

	Unaudited Six months to 31 May 2021 £'000	Unaudited Six months to 31 May 2020 £'000	Audited Year to 30 November 2020 £'000
Cash flows from operating activities			
Profit/(loss) before tax	24,701	(2,036)	17,762
Adjustments for:			
Decrease/(Increase) in debtors	62	(921)	14
(Decrease)/increase in creditors	(782)	413	437
Gain/(loss) on disposal of fixed asset investments	(1,552)	378	(433)
Gain/(loss) on disposal of current asset investments	(33)	42	158
Gain/(loss) on valuation of fixed asset investments	(21,415)	601	(17,871)
Gain/(loss) on valuation of current asset investments	(2,680)	225	(1,126)
Non-cash distributions	(109)	-	(41)
Cash from operations	(1,808)	(1,298)	(1,100)
Income taxes paid	-	-	-
Net cash generated from operating activities	(1,808)	(1,298)	(1,100)
Cash flows from investing activities			
Purchase of fixed asset investments	(5,296)	(3,898)	(4,518)
Proceeds from sale of fixed asset investments	4,164	2,298	5,214
Purchase of current asset investments	(2,380)	(389)	(2,471)
Proceeds from sale of current asset investments	3,359	1,000	9,500
Net cash flows from investing activities	(153)	(989)	7,725
Cash flows from financing activities			
Purchase of own shares	(2,875)	(1,521)	(2,710)
Share issues	9,502	9,425	14,104
Share issue costs	(643)	(617)	(908)
Dividends paid	(2,278)	(2,064)	(4,142)
Net cash flows from financing activities	3,706	5,223	6,344
Increase in cash and cash equivalents	1,745	2,936	12,969
Opening cash and cash equivalents	18,324	5,355	5,355
Closing cash and cash equivalents	20,069	8,291	18,324
Closing cash and cash equivalents is represented by:			
Cash at bank	16,583	4,806	14,838
Money market funds	3,486	3,485	3,486
Total cash and cash equivalents	20,069	8,291	18,324

Notes to the Half-Yearly Report

1. Basis of preparation

The unaudited half-yearly report which covers the six months to 31 May 2021 has been prepared in accordance with the Financial Reporting Council's (FRC) Financial Reporting Standard (FRS) 104 Interim Financial Reporting (March 2018) and the Statement of Recommended Practice (SORP) for Investment Companies issued by the Association of Investment Companies in 2014 (updated in February 2018).

The Directors consider it appropriate to adopt the going concern basis of accounting. The Directors have not identified any material uncertainties to the company's ability to continue to adopt the going concern basis over a period of at least twelve months from the date of approval of the financial statements. In reaching this conclusion the Directors have had regard to the potential impact on the economy and the Company of the current Coronavirus pandemic.

The principal accounting policies have remained unchanged from those set out in the Company's 2020 Annual Report and Accounts.

2. Publication of non-statutory accounts

The unaudited half-yearly report for the six months ended 31 May 2021 does not constitute statutory accounts within the meaning of Section 415 of the Companies Act 2006. The comparative figures for the year ended 30 November 2020 have been extracted from the audited financial statements for that year, which have been delivered to the Registrar of Companies. The independent auditor's report on those financial statements, in accordance with chapter 3, part 16 of the Companies Act 2006, was unqualified. This half-yearly report has not been reviewed by the Company's auditor.

3. Earnings per share

The earnings per share at 31 May 2021 are calculated on the basis of 134,206,472 shares (31 May 2020: 115,920,374 and 30 November 2020: 118,842,639), being the weighted average number of shares in issue during the period.

There are no potentially dilutive capital instruments in issue and, therefore, no diluted returns per share figures are relevant.

4. Net asset value per share

The net asset value per share is based on net assets as at 31 May 2020 divided by 133,577,697 shares in issue at that date (31 May 2020: 121,145,852 and 30 November 2020: 125,660,654).

5. Dividends

The Directors have declared an interim dividend of 2.1 pence per share and a special dividend of 1.7 pence per share, payable from the special distributable reserve. This dividend will be paid on 12 November 2021 to those shareholders on the register at 15 October 2021.

6. Buybacks and share issues

During the six months ended 31 May 2021 the Company repurchased the following shares.

Date	No. of shares	Price (p)	Cost (£)
10 December 2020	557,881	81.1	453,000
21 January 2021	470,810	86.7	408,000
25 February 2021	456,958	90.8	415,000
18 March 2021	555,254	91.7	509,000
22 April 2021	682,938	95.2	650,000
20 May 2021	471,138	93.4	440,000
Total	3,194,979		2,875,000

The weighted average price of all buybacks during the period was 90.0 pence per share.

During the six months ended 31 May 2021 the Company issued the following shares:

Date	No. of shares	Price (p)	Net proceeds (£)
09 December 2020	10,527,955	89.8	8,814,000
15 April 2021	45,548	104.0	45,000
21 May 2021 (DRIS)	538,519	97.7	526,000
Total	11,112,022		9,385,000

The weighted average allotment price of all shares issued during the period net of costs was 84.4 pence per share.

The total value of share issues, net of share issue costs, was £8,859,000 (excluding the value of shares issued under DRIS). This is shown in the cash flow statement.

7. Principal risks and uncertainties

The Company's principal risks are VCT qualifying status risk, valuation risk, investment risk, finance risk, regulatory and reputational risk, economic and price risk and operational risk. These risks, and the way in which they are managed, are described in more detail in the Company's Annual Report and Accounts for the year ended 30 November 2020. The Board has also considered emerging risks, including the Coronavirus pandemic, which the Board seeks to mitigate by setting policy and reviewing performance. Otherwise, the Company's principal risks and uncertainties have not changed materially since the date of that report.

8. Related party transactions

The Company has employed Octopus Investments Limited (“Octopus” or “the Manager”) throughout the period as Investment Manager. Octopus has also been appointed as Custodian of the Company’s investments under a Custodian Agreement. The Company has been charged £873,000 by Octopus as a management fee in the period to 31 May 2021 (31 May 2020: £647,000 and 30 November 2020: £1,335,000). The management fee is payable quarterly and is based on 2% of net assets at quarterly intervals.

The Company receives a reduction in the management fee for the investments in other Octopus managed funds, being the Octopus Portfolio Manager, Multi Cap and Micro Cap products, to ensure the Company is not double charged on these products. This amounted to £30,000 in the period to 31 May 2021 (31 May 2020: £31,000 and 30 November 2020: £54,000). For further details please refer to the Company’s Annual Report and Accounts for the year ended 30 November 2020. Details of amounts invested in Octopus managed funds can be found on page 13.

9. Post balance sheet events

The following events occurred between the balance sheet date and the signing of these financial statements:

- An investment of £600,000 into VR Education Holdings plc;
- An investment of £1,410,199 into Spectral MD Holdings Ltd;
- An investment of £1,386,000 into LungLife AI Inc;
- An investment of £800,000 into GENInCode plc;
- Partial disposal of Trackwise Designs plc for a consideration of £31,137;
- Partial disposal of Intelligent Ultrasound plc for a consideration of £30,733;
- Partial disposal of PCI Pal plc for a consideration of £135,596;
- Partial disposal of Ergomed plc for a consideration of £31,137;
- Partial disposal of Gear4music Holdings plc for a consideration of £131,583;
- On 11 June 2021, the Company purchased for cancellation 305,750 Ordinary Shares at a price of 95.7p;
- On 30 June 2021, the Company issued 38,403 Ordinary Shares at a price of 98.1p.

10. Fixed asset investments

Accounting Policy

The Company's principal financial assets are its investments and the policies in relation to those assets are set out below.

Purchases and sales of investments are recognised in the financial statements at the date of the transaction (trade date).

These investments will be managed and their performance evaluated on a fair value basis in accordance with a documented investment strategy and information about them has to be provided internally on that basis to the Board. Accordingly, as permitted by FRS 102, the investments are measured as being fair value through profit or loss on the basis that they qualify as a group of assets managed, and whose performance is evaluated, on a fair value basis in accordance with a documented investment strategy. The Company's investments are measured at subsequent reporting dates at fair value.

In the case of investments quoted on a recognised stock exchange, fair value is established by reference to the closing bid price on the relevant date or the last traded price, depending upon convention of the exchange on which the investment is quoted. This is consistent with the International Private Equity and Venture Capital Valuation (IPEV) guidelines.

Gains and losses arising from changes in fair value of investments are recognised as part of the capital return within the Income Statement and allocated to the Capital reserve – unrealised. The Managers review changes in fair value of investments for any permanent reductions in value and will give consideration to whether these losses should be transferred to the Capital reserve – realised.

In the preparation of the valuations of assets the Directors are required to make judgements and estimates that are reasonable and incorporate their knowledge of the performance of the investee companies.

Fair value hierarchy

Paragraph 34.22 of FRS102 suggests following a hierarchy of fair value measurements, for financial instruments measured at fair value in the Balance Sheet, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). This methodology is adopted by the Company and requires disclosure of financial instruments to be dependent on the lowest significant applicable input, as laid out below:

Level 1: The unadjusted, fully accessible and current quoted price in an active market for identical assets or liabilities that an entity can access at the measurement date.

Level 2: Inputs for similar assets or liabilities other than the quoted prices included in Level 1 that are directly or indirectly observable, which exist for the duration of the period of investment.

Level 3: This is where inputs are unobservable, where no active market is available and recent transactions for identical instruments do not provide a good estimate of fair value for the asset or liability.

There has been two reclassifications from Level 2 to Level 1. These relate to Reneuron Group plc and DP Poland where these investments were not actively trading at previous year end but are trading in the period to May 2021. Other than this, there have been no reclassifications between levels in the year. The change in fair value for the current and previous year is recognised through the profit and loss account.

Disclosure

	Level 1: Quoted equity investments £'000	Level 2: Quoted equity investments £'000	Level 3: Unquoted investments £'000	Total £'000
Cost as at 1 December 2020	34,225	1,694	2,595	38,514
Opening unrealised gain at 1 December 2020	36,899	(631)	1,913	38,181
Valuation at 1 December 2020	71,124	1,063	4,508	76,695
Purchases at cost	4,896	–	400	5,296
In-Specie dividend	109	–	–	109
Disposal proceeds	(3,966)	–	(198)	(4,164)
Profit/(loss) on realisation of investments	1,433	–	119	1,552
Reclassification between levels	1,063	(1,063)	–	–
Change in fair value in year	21,410	–	5	21,415
Closing valuation at 31 May 2021	96,069	–	4,834	100,903
Cost at 31 May 2021	39,758	–	2,807	42,565
Closing unrealised gain at 31 May 2021	56,311	–	2,027	58,338
Valuation at 31 May 2021	96,069	–	4,834	100,903

Level 1 valuations are valued in accordance with the bid-price on the relevant date. Further details of the fixed asset investments held by the Company are shown within the Investment Manager's Review.

Level 2 investments are valued using other observable inputs not included in Level 1. Reneuron Group plc was valued at previous year end partly at closing market bid price and partly at a fixed fundraise price. DP Poland was also valued at a closing price, the day before suspension took effect. Since year end these investments are actively trading.

Level 3 investments are valued in accordance with IPEV guidelines. Hasgrove plc is valued using a range of inputs, including the most recent transaction price, whilst Rated People Ltd and Popsa Holdings Ltd is valued at the latest fundraise price. Fusionex International plc and Airnow Group plc are held at the latest available price. The loan notes are held at cost which is deemed to be current fair value.

All capital gains or losses on investments are classified at FVTPL. Given the nature of the Company's venture capital investments, the changes in fair value of such investments recognised in these financial statements are not considered to be readily convertible to cash in full at the balance sheet date and accordingly these gains are treated as holding gains or losses.

At 31 May 2021 there were no commitments in respect of investments approved by the Investment Manager but not yet completed.

11. Additional information

Copies of this report are available from the registered office of the Company at 33 Holborn, London, EC1N 2HT.

About Octopus AIM VCT 2 plc

The Company was launched as Close IHT AIM VCT plc and raised £25 million in March 2006 through an offer for subscription.

On 12 August 2010 the Company acquired the assets and liabilities of Octopus Third AIM VCT plc (formerly Octopus Second AIM VCT plc) ("the merger") and changed its name from Octopus IHT AIM VCT plc to Octopus Second AIM VCT plc. Shareholders of Octopus Third AIM VCT received 0.48356191 Ordinary shares in the Company for each Ordinary share they held prior to the merger. Prior to July 2009 Octopus Third AIM had two classes of shares, Ordinary and C shares. The C shares converted into Ordinary shares in July 2009 and C shareholders received 2.4313 Ordinary shares for each C share held. The prospectus also raised a total of £6.4 million for the Company.

A Top-up offer launched on 6 February 2012 and which closed on 5 April 2012, which raised £1.3 million for the Company. A Top-up offer was launched on 25 April 2012 and closed on 31 July 2012, which raised a further £0.5 million for the Company.

On 1 February 2013, the Board launched an offer for subscription with the target of raising £10.0 million for the Company. The offer closed on 17 January 2014, having raised £5.9 million.

On 30 January 2014, the Company name changed to Octopus AIM VCT 2 plc.

A combined new share offer was launched on 3 February 2014 to raise up to £4.1 million. This closed on 28 March 2014, fully subscribed.

A combined fundraise with Octopus AIM VCT plc was launched on 29 August 2014 to raise up to £8 million with an over-allotment facility of £4 million. This offer closed, fully subscribed, on 11 August 2015.

The Board decided to open a further Offer for subscription, again combined with Octopus AIM VCT plc, to raise up to £8 million with an over-allotment facility of £4 million on 21 December 2015. This Offer closed, fully subscribed, on 21 October 2016.

A Top-up offer launched on 6 February 2017 to raise up to £4.3 million, and closed fully subscribed on 18 April 2017.


A combined fundraise with Octopus AIM VCT plc was launched on 16 June 2017 to raise up to £12 million for the Company with an over-allotment facility of £4 million, and closed fully subscribed on 14 November 2017.

On 3 August 2018 a prospectus offer was launched alongside Octopus AIM VCT plc to raise up to £8 million with a £4 million over allotment facility. This prospectus closed to new applications fully subscribed 28 September 2018.

A combined fund raise with Octopus AIM VCT plc by way of an issue of new shares was launched on 29 November 2019 to raise up to £8 million for the Company with an over-allotment facility of £4 million. This offer closed, fully subscribed, on 27 February 2020.

On 20 August 2020, a prospectus offer was launched alongside Octopus AIM VCT plc to raise a combined total of up to £8 million with a £4 million over allotment facility. This prospectus closed to further applications on 30 November 2020.

The tables below depict the Net Asset Value (NAV) per share and the dividends that have been paid since the launch of Octopus AIM VCT 2 plc for the different share classes. The figures represent the NAV, rebased to assume investment (including initial charge) at 100p, and adjusted in accordance with the relevant conversion factors. Investment has been assumed at the first allotment of each tax year:



Dividends paid during the period ending	Octopus AIM VCT 2 Ordinary shares 2021/22	Octopus AIM VCT 2 Ordinary shares 2020/21	Octopus AIM VCT 2 Ordinary shares 2019/20	Octopus AIM VCT 2 Ordinary shares 2018/19	Octopus AIM VCT 2 Ordinary shares 2017/18	Octopus AIM VCT 2 Ordinary shares 2016/17	Octopus AIM VCT 2 Ordinary shares 2015/16
30 November 2003					-	-	-
30 November 2004					-	-	-
30 November 2005					-	-	-
30 November 2006					-	-	-
30 November 2007					-	-	-
30 November 2008					-	-	-
30 November 2009					-	-	-
30 November 2010					-	-	-
30 November 2011					-	-	-
30 November 2012					-	-	-
30 November 2013					-	-	-
30 November 2014					-	-	-
30 November 2015					-	-	7.0*
30 November 2016					-	4.8*	4.6*
30 November 2017					4.5*	4.9*	4.8*
30 November 2018				4.5*	4.6*	5.0*	4.9*
30 November 2019			9.8*	8.7*	8.9*	9.7*	9.4*
30 November 2020		6.0*	5.1*	4.5*	4.6*	5.0*	4.9*
30 November 2021	2.0*	3.0*	2.5*	2.3*	2.3*	2.5*	2.4*
Total dividends paid (assumed investment at 100p)	2.0	9.0	17.5	20.0	24.8	31.8	37.9
Adjusted NAV (assumed investment at 100p)	95.4p	141.3p**	120.2**	86.9**	108.5**	118.2**	115.1**
NAV plus total dividends (assumes investment at 100p)	97.4	150.3***	137.7***	106.9***	133.4***	150.1***	153.0***

Following the merger with Octopus Third AIM VCT plc and various share re-organisations, there is now only one share class, Ordinary shares. For Octopus Third AIM VCT Ordinary shares and 'C' & 'D' shares, the figures above represent a notionally adjusted NAV per share in accordance with the relevant conversion factors.

Octopus AIM VCT 2 Ordinary shares 2014/15	Octopus AIM VCT 2 Ordinary shares 2013/14	Octopus AIM VCT 2 Ordinary shares 2012/13	Octopus AIM VCT 2 Ordinary shares 2011/12	Octopus AIM VCT 2 Ordinary shares 2010/11	Octopus Second AIM VCT (formerly Octopus IHT AIM VCT A&B shares) 2005/06	Octopus Third AIM VCT C&D shares 2005/06 (formerly Octopus Second AIM VCT)	Octopus Third AIM Ordinary shares 2000/01 shares (formerly Octopus Second AIM VCT plc)
-	-	-	-	-	-	-	1.6
-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-
-	-	-	-	-	1.4	-	1
-	-	-	-	-	2.0	0.8	7
-	-	-	-	-	2.0	2.2	11
-	-	-	-	-	2.0	2.0	2
-	-	-	-	-	2.5	5.4	2.2
-	-	-	-	4.7*	3.3	3.9*	1.6*
-	-	2.3*	4.4*	4.6*	3.2	3.8*	1.6*
-	4.5*	5.1*	4.7*	5.0*	3.5	4.1*	1.7*
4.3*	5.2*	5.8*	5.4*	5.8*	4.0	4.7*	1.9*
6.4*	7.8*	8.7*	8.1*	8.6*	6.0	7.1*	2.9*
4.3*	5.2*	5.8*	5.4*	5.8*	4.0	4.7*	1.9*
4.4*	5.3*	5.9*	5.5*	5.9*	4.1	4.8*	2.0*
4.5*	5.5*	6.1*	5.6*	6.0*	4.2	4.9*	2.0*
8.6*	10.5*	11.7*	10.9*	11.6*	8.1	9.5*	3.9*
4.5*	5.5*	6.1*	5.6*	6.0*	4.2	4.9*	2.0*
2.2*	2.7*	3.0*	2.8*	3.0*	2.1*	2.5*	1.0*
39.1	52.2	60.6	58.5	67.1	56.6	65.2	47.4
105.6**	128.8**	143.8**	133.3**	142.7**	99.2	116.6**	48.0**
144.7***	181.0***	204.4***	191.8***	209.8***	155.8	181.9***	95.4***

*Notional dividends assuming investment at 100p and adjusting for conversion of various share classes into Octopus AIM VCT 2 plc Ordinary shares.

**NAV assuming investment at 100p and adjusting for conversion of various share classes into Octopus AIM VCT 2 plc Ordinary shares.

***NAV plus cumulative dividends adjusting for conversion, assuming investment at 100p showing the notional return to shareholders based on their original investment share class.

Notes

- Octopus Third AIM VCT 'D' shares converted into 'C' shares in May 2009, in accordance with a conversion factor of 1 'C' share for each 'D' share.
- Octopus Third AIM VCT 'C' shares converted into Octopus Third AIM VCT Ordinary shares in May 2009, in accordance with a conversion factor of 2.4313 Ordinary shares for each 'C' share.
- Octopus AIM VCT 2 plc (previously Octopus IHT AIM VCT) 'B' shares converted into 'A' shares in May 2009, in accordance with a conversion factor of 1 'A' share for each 'B' share.
- Octopus Third AIM Ordinary shares converted into Octopus AIM 2 (post August 2010) Ordinary shares in August 2010, in accordance with a conversion factor of 0.48356191 Octopus AIM 2 Ordinary share (post August 2010), for each Octopus Third AIM Ordinary share.
- In August 2010, Octopus IHT AIM VCT was renamed Octopus Second AIM VCT, and subsequently changed its name to Octopus AIM VCT 2 plc.

Directors and Advisers

Board of Directors

Keith Mullins (Chairman)
Andrew Raynor FCA
Elizabeth Kennedy
Alastair Ritchie

Secretary and Registered office

Octopus Company Secretarial Services
Limited
33 Holborn
London
EC1N 2HT

Investment and Administration Manager

Octopus Investments Limited
33 Holborn
London
EC1N 2HT
Tel: 0800 316 2349
www.octopusinvestments.com

Custodians

Octopus Investments Limited
33 Holborn
London
EC1N 2HT

Bankers

HSBC Bank plc
31 Holborn
London
EC1N 2HR

Independent Auditor

BDO LLP
55 Baker Street
London
W1U 7EU

Taxation Advisor

PricewaterhouseCoopers LLP
1 Embankment Place
London
WC2N 6RH

VCT Status Adviser

PricewaterhouseCoopers LLP
1 Embankment Place
London
WC2N 6RH

Registrar

Computershare Investor Services PLC
The Pavilions
Bridgewater Road
Bristol
BS99 6ZZ
Tel: 0370 703 6326
Calls are charged at the standard geographic rate and will vary by provider. Calls from outside the United Kingdom will be charged at the applicable international rate.
www.computershare.com/uk
www-uk.computershare.com/investor/

Corporate Broker

Panmure Gordon (UK) Limited
One New Change
London
EC4M 9AF
020 7886 2500



0800 316 2295
info@octopusinvestments.com
octopusinvestments.com



Octopus Investments,
33 Holborn,
London EC1N 2HT